Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Superior Treatment against HPV Throat Cancer is Catching On; The Center for the Biology of Chronic Disease (CBCD) Recommends Novirin against the Latent HPV
  • USA - English


News provided by

CBCD

Mar 16, 2015, 00:00 ET

Share this article

Share toX

Share this article

Share toX


Rochester, NY (PRWEB) March 16, 2015 -- “Infected with the human papillomavirus (HPV)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement.” - Greg Bennett, CBCD

The CBCD is encouraged by the development of newer, safer treatments against HPV caused cancers. The problem, as we see it, is that none of these treatments targets the source of the disease. - Greg Bennett, CBCD

Post this

Doctors face a difficult choice. When treating HPV caused throat cancer, they need to choose between two terrible outcomes. They can let the patient die from cancer, or they can treat them with a combination of chemotherapy or radiotherapy, which can also kill the patient. However, new surgical techniques called transoral surgical techniques (TOS), reduce the need for these doctors to choose. As authors of a new study noted, “functional outcomes may be superior following TOS treatment.” (1) TOS is important since the rate of human papilloma (HPV) caused throat cancer (HPV related oropharyngeal squamous cell carcinoma) is increasing at epidemic rates.

Dr. Hinni and colleagues wrote that “Oncologists are recognizing a changing pattern in the cause of oropharyngeal cancer, namely the increasing incidence of HPV-associated tumors. An effort is underway to reduce the morbidity of treatment without jeopardizing survival.” (1) Dr. Hinni is from the Mayo Clinic College of Medicine in Phoenix, Arizona. Importantly, however, the authors also noted that “management of oropharyngeal SCC will most likely continue to be multidisciplinary.” (1) In other words, doctors will most likely use a combination of treatments in addition to TOS against HPV throat cancers. With this in mind, the CBCD recommends that HPV infected individuals take Novirin. The formula of this natural, antiviral product was designed to help the immune system target the latent form of the HPV virus.

Click to learn more about Novirin and the HPV virus.

The formula of Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy. The first study was published in a special edition on Advances in Antiviral Drugs.

Study authors wrote that, “individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with (the formula of Novirin).” (2) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Novirin can be ordered online on the Novirin website here: http://www.novirin.com.

Novirin is a natural antiviral dietary supplement. Its formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose were chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Novirin is the only natural antiviral product on the market with published clinical studies that support its claims.

A study showed that “over the past decade there has been an increase in the incidence of oropharyngeal cancer, especially among individuals under the age of 45 years, which has been attributed to human papilloma virus (HPV) infection. Nonsurgical or organ preserving therapies, which utilize combinations of chemotherapy and radiotherapy (RT), have become popular treatments for advanced stage oropharyngeal cancers. However, long-term follow-up studies have failed to demonstrate superior survival rates. In addition, RT with concurrent chemotherapy is associated with a high rate of severe acute toxicities in the majority of patients, late swallowing dysfunction, and a mortality rate.” (See Laryngoscope, from September 2009) (3)

What this means, is that until recently, both chemotherapy and radiotherapy were used to treat HPV throat cancer. However, both treatments caused negative health effects. In other words, the treatments poisoned the patients and caused just as much damage as the cancer!

However, patients who undergo transoral surgical techniques (TOS) have a much higher, long-term survival rate. One of these surgical techniques is called transoral laser microsurgery (TLM), and “is a minimally invasive … surgical technique that offers a locally targeted treatment, relatively rapid recovery, and a low long-term toxicity profile.” (3)

“The CBCD is encouraged by the development of newer, safer treatments against HPV caused cancers. The problem, as we see it, is that none of these treatments targets the source of the disease. TOS do not target the HPV virus, but rather the tumors caused by the virus.” – Greg Bennett, CBCD

How is HPV transmitted?

“Some types of HPV infection can develop without sexual relations, but often HPV is passed from one person to another during intimate contact including open mouth kissing, skin-to-skin contact, oral contact with genitalia, and vaginal and/or anal sex.” (See MetroJacksonville.com, from August 7, 2014) (4)

“There are 109 known different types of human papillomaviruses (HPV). They cause warts and other lesions and two in particular, HPV 16 and HPV 18, cause cancers of the cervix, anus and penis, as well as the mouth and throat. Types 6 and 11 can cause lesions and genital warts.” (See NBC News, from May 20, 2014) (5)

What other treatments are available against the HPV?

“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (2)

In contrast, Novirin was designed to target the latent HPV.

Individuals interested in viewing published studies on the formula of Novirin can go here:

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-s9ouOSz90

and

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.U-s9w-OSz90

Click to learn more about Novirin and HPV.

All orders of Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Hinni ML1, Nagel T, Howard B. "Oropharyngeal cancer treatment: the role of transoral surgery." Curr Opin Otolaryngol Head Neck Surg. 2015 Apr;23(2):132-8.
http://www.ncbi.nlm.nih.gov/pubmed/25761152

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-s9ouOSz90

(3) Jason T. Rich, MD, Simon Milov, MD, James S. Lewis, Jr., MD, Wade L. Thorstad, MD, Douglas R. Adkins, MD, and Bruce H. Haughey, MBChB "Transoral Laser Microsurgery (TLM) ± Adjuvant Therapy for Advanced Stage Oropharyngeal Cancer: Outcomes and Prognostic Factors." Laryngoscope. 2009 Sep; 119(9): 10.1002/lary.20552.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877921/

(4) Metrojacksonville.com - Risky Business: Adolescent Sexual Behavior and HPV. Published August 7, 2014.
metrojacksonville.com/article/2014-aug-risky-business-adolescent-sexual-behavior-and-hpv#.U-sPfOOSz90

(5) Fox, M. HPV Found in Two-Thirds of Americans, Survey Finds. Published on May 20, 2014.
nbcnews.com/health/health-news/hpv-found-two-thirds-americans-survey-finds-n109846

Greg Bennett, CBCD, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.